Cite
HARVARD Citation
Sakai, D. et al. (2020). Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). European journal of cancer. pp. 11-21. [Online].